Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE IIB, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF CSJ117, WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS ¿ 18 YEARS OF AGE WITH SEVERE UNCONTROLLED ASTHMA

Intervention/treatment:
CSJ117
Medical condition:
ASTHMA
Protocol code:
CCSJ117A12201C
Control number:
244931
Status:
Closed
Approved:
November 13, 2020
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT04410523
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Study Director
Organization
Novartis Pharmaceuticals
Phone:
862-778-8300
Sponsor
NOVARTIS PHARMACEUTICALS CANADA INC

Locations

Ontario

Novartis Investigative Site
Ajax, Ontario, L1S 2J5
Novartis Investigative Site
Burlington, Ontario, L7N 3V2
Novartis Investigative Site
Etobicoke, Ontario, M9V 4B4
Novartis Investigative Site
Hamilton, Ontario, L8N 3Z5

Quebec

Novartis Investigative Site
Montreal, Quebec, H2V 2K1
Novartis Investigative Site
Trois-Rivières, Quebec, G8T 7A1

Results

See the results from the trial NCT04410523. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?